IPF

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BiocorpFrance - Issoire

2 programs

AMB-05XPhase 2

HW252001Phase 11 trial

Active Trials

NCT07493031Not Yet Recruiting98Est. Dec 2026

Orion PharmaUK - Reading

1 program

RXC007Phase 2

OrionUK - Cambridge

1 program

RXC007Phase 2

Redx PharmaUK - Macclesfield

1 program

RXC007Phase 21 trial

Active Trials

NCT05570058Active Not Recruiting48Est. Jan 2025

SPARK BiopharmaKorea - Seoul

1 program

SB17170Phase 21 trial

Active Trials

NCT06747923Recruiting30Est. Oct 2026

Agomab TherapeuticsBelgium - Antwerpen

1 program

AGMB-447Phase 11 trial

Active Trials

NCT06181370Recruiting145Est. Jun 2026

Henovcom BioscienceChina - Guangzhou

1 program

HNC1058 CapsulesPhase 11 trial

Active Trials

NCT05803850Completed32Est. Mar 2024

Colorado TherapeuticsCO - Louisville

1 program

Sample collectionN/A

Angeles TherapeuticsCA - Los Angeles

1 program

Sample collectionN/A1 trial

Active Trials

NCT04564183Active Not Recruiting800Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

SPARK BiopharmaSB17170

Redx PharmaRXC007

BiocorpHW252001

Agomab TherapeuticsAGMB-447

Henovcom BioscienceHNC1058 Capsules

Angeles TherapeuticsSample collection

Clinical Trials (6)

Total enrollment: 1,153 patients across 6 trials

NCT06747923 SPARK BiopharmaSB17170

SB17170 Phase 2 Trial in IPF Patients

Start: Jan 2025Est. completion: Oct 202630 patients

Phase 2Recruiting

NCT05570058 Redx PharmaRXC007

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Start: Sep 2022Est. completion: Jan 202548 patients

Phase 2Active Not Recruiting

NCT07493031 BiocorpHW252001

A PhaseⅠ Study of HW252001 in Healthy Subjects

Start: Mar 2026Est. completion: Dec 202698 patients

Phase 1Not Yet Recruiting

NCT06181370 Agomab TherapeuticsAGMB-447

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

Start: Dec 2023Est. completion: Jun 2026145 patients

Phase 1Recruiting

NCT05803850 Henovcom BioscienceHNC1058 Capsules

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Start: Mar 2023Est. completion: Mar 202432 patients

Phase 1Completed

NCT04564183 Angeles TherapeuticsSample collection

Advancing Prevention of Pulmonary Fibrosis

Start: Jan 2021Est. completion: Aug 2026800 patients

N/AActive Not Recruiting

Related Jobs

Senior Director, Regulatory Affairs

Contineum Therapeutics

Remote

1mo ago

$240K - $265K/yr

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,153 patients

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.